OBJECTIVE To compare the efficacy of 0.1% tacrolimus (FK-506) ophthalmic ointment with 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis (VKC). DESIGN Prospective double-masked randomized comparative trial. PARTICIPANTS Twenty-four VKC patients were enrolled into the study. Their mean age was 9.61 +/- 2.55 years. Twelve patients were allocated into the FK-506 group a...

OBJECTIVES We studied rejection, allograft function and side effects, such as hypertension, renal dysfunction and hypercholesterolemia, in seven patients switched from cyclosporine-based triple-drug immunosuppression to FK 506. BACKGROUND A subset of pediatric heart transplant recipients treated with triple-drug immunosuppression consisting of cyclosporine, azathioprine and prednisone experie...

BETWEEN 12 and 18 months ago we treated three patients with FK S06 who had severe psoriasis that was refractory to conventionai therapy and four patients with w,despread incidental psonasis before undergoing hean or liver transplantation under FK 506. All had dramatic resolution of psonasis. which remaIned in remission as long as full-dose therapy was provided. Serial skin biopsies had a rapid ...

BACKGROUND AND PURPOSE Transplantation conditioning regimens have been shown to affect the brain imaging appearance in patients with cyclosporine or FK-506 neurotoxicity. We assessed whether the occurrence of neurotoxicity was affected by the choice of conditioning regimen used before allogeneic bone marrow transplantation (allo-BMT). METHODS An allo-BMT was performed in 290 patients conditio...

BACKGROUND Drugs released from stents affect the biology of vascular cells. We examined the effect of rapamycin and FK-506 on tissue factor (TF) expression in human aortic endothelial cells (HAECs) and vascular smooth muscle cells (HAVSMCs). METHODS AND RESULTS Rapamycin enhanced thrombin- and tumor necrosis factor (TNF)-alpha-induced endothelial TF expression in a concentration-dependent man...

F K 506 is a powerful new investigational immunosup-. pressant that has been used successfully first as an organ rescue agent and then as a primary antirejection agent. FK 506 has been shown to have a favorable profile on pancreatic islets in vitro'; however, the agent does decrease glucose-induced insulin release at high concentrations from bo~ rodent 2 • 3 and human islets. 2 This agent also ...